Rheumatoid arthritis (RA) is a chronic immune-mediated condition with enormous socioeconomic and individual impact. Despite the availability of various treatment options, every patient seems to respond differently. Furthermore, the unsuccessful choice of the most suitable medication for a particular patient can lead to a scenario in which the patient consumes a drug that doesn’t align with their body’s response, ultimately aggravating the patient’s condition. We, at SQUEEZE, in synergy with other EU-wide activities, work to validate clinical, laboratory, molecular, digital, and behavioural biomarkers to help tailor the best treatment to the individual patient. Our aim is to improve the efficacy, safety, and satisfaction with existing therapies (by squeezing the most out of them!).